Development of Products, Tools, and Technologies to Accelerate Development of Key Marker Panels for the Personalized Treatment of PDA
AIkido Pharma Inc. (Nasdaq: AIKI) today announced that its work with research partner, Cogia BioTech LTD (www.cogia.de), has delivered several key updates on efforts to accelerate the study of PDA (Pancreatic Ductal Adenocarcinoma) treatments. As previously reported, the Company executed a Scientific Research Agreement with The University of Texas Southwestern Medical Center and Cogia to use machine learning to find genetic markers in people that indicate an increased risk of developing pancreatic cancer.
Cogia Biotech, a Big-data, Artificial Intelligence (AI), and Machine Learning (ML) software company committed to using powerful AI engines and algorithms to develop compelling outcomes in drug development, released a comprehensive progress report to AIkido which included:
The identification of clusters of markers that interact in signaling pathways affecting PDA survival.
The development of products and tools to provide extensive information on PDA markers to guide personalized medicine.
The assembly of survival associations of individual markers from ONCOLNC.org into sets that will help identify novel targets in PDA.
Information about gene and protein function in human PDA patients and human PDA cancer cell lines to help prioritize individual diagnostic markers.
Anthony Hayes, CEO of AIkido stated, "We are extremely pleased with the progress that Cogia has made in this research project, and are enthusiastic about their continued efforts to develop panels of markers that will rapidly identify patients who have initiated early events in pancreatic cancer. Cogia's Diagnostic Assay Application and Prognostic Marker Characterization Application products assemble essential information on antibodies specific to the respective proteins for more than 20,000 antibody reagents and utilizes the unsupervised learning protocols of the Cogia AI/ML engine to identify clusters of similarly expressed genes, and their association with PDA subtypes. These tools establish the building blocks of what we continue to believe will be an even broader set of usable full-service products and tools for ongoing and more expanded PDA diagnostics, prognostics, and therapeutics.
About AIkido
AIkido was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Aikido Pharma Has Licensed DHA-dFdC at The University of Texas at Austin
Released On: 3/5/2021
Views: 932
Aikido Pharma Shares Published Papers and Articles on KPC-34 and DHA-dFdC
Released On: 3/3/2021
Views: 914
Aikido Pharma Announces Findings of Positive Results From New Drug “DHA-dFdC” Developed at The University of Texas at Austin
Released On: 3/1/2021
Views: 942
AIkido Pharma Inc. to Present at the H.C. Wainwright Global Life Sciences Conference (Virtual Event)
Released On: 3/1/2021
Views: 1351
Meet Aikido Pharma Inc’s Board of Directors
Released On: 2/28/2021
Views: 961
AIkido Pharma Inc. Announces Exercise of Option to Purchase Additional Shares in Bought Deal Offering
Released On: 2/23/2021
Views: 981
Artificial Intelligence Is Optimizing Drug Development
Released On: 2/22/2021
Views: 1009
Aikido Pharma Focuses on The Treatment of Four Main Types of Cancer
Released On: 2/20/2021
Views: 890
AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock
Released On: 2/19/2021
Views: 1046
AIkido Pharma Inc. Increases Previously Announced Bought Deal Offering of Common Stock to $75 Million
Released On: 2/16/2021
Views: 1141
AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock
Released On: 2/16/2021
Views: 1094
AIkido Pharma Enters Into Letter Of Intent With Silo Pharma for Use of Psilocybin and Peptide Therapy for Cancer Treatment
Released On: 2/16/2021
Views: 1234
Aikido Pharma Announces Information on KPC-34 Which Was Developed at the Wake Forest School of Medicine
Released On: 2/15/2021
Views: 892
Aikido Pharma Establishes Licensing Agreement with University of Maryland
for Antiviral Compounds, Including COVID-19
Released On: 2/10/2021
Views: 803
Aikido Pharma Announces DHA-dFdC Which Is Licensed From the University of Texas at Austin for the treatment of Pancreatic Cancer.
Released On: 2/9/2021
Views: 1404
Aikido Pharma Secures Early Interest in Convergent Therapeutics, Inc. Who Focuses On Next Generation Radiopharmaceutical Therapy for Prostate Cancer
Released On: 2/5/2021
Views: 979
AIkido Pharma Appoints Dr. Scott T. Tagawa, M.D. to Scientific Advisory Board
Released On: 2/3/2021
Views: 1854
Meet Aikido Pharma A BioTechnology Development Company Focused on The Treatment Of Early and Mid-Stage Small-Molecule Anti-Cancer Therapeutics
Released On: 2/3/2021
Views: 1077